CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20

CEL-SCI (CVM) Corporation announced that during its annual shareholder’s meeting on May 19, a combination was authorized for its outstanding shares of common stock. On May 19, the board of directors approved a 1 for 30 combination of common stock. CEL-SCI expects the combination to be implemented on May 20. When the market opens on May 20, the common stock will trade under a new CUSIP number 150837 706, but the company’s ticker symbol, CVM, will remain unchanged. “We believe that the next few months may present us with a number of major catalysts. Hopefully this will lead to more interest from investors. The combination of common stock is needed for two reasons: our low stock price prohibits many funds from investing in CEL-SCI and the major US stock exchanges have made it clear that they want listed companies to have a higher share price. Therefore we believe that this is an appropriate time to implement a combination that will bring our share price to levels where more investors, as well as funds, can buy and trade our stock. We appreciate the continued support of our shareholders as we advance our investigational drug and drug candidates through our clinical development program with a goal towards delivering better treatment alternatives for cancer, autoimmune and infectious diseases,” stated CEL-SCI CEO Geert Kersten.